- Home
- CJET vs RLMD Comparison
CJET vs RLMD Comparison
Compare CJET & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- RLMD
- Stock Information
- Founded
- CJET 2009
- RLMD 2004
- Country
- CJET China
- RLMD United States
- Employees
- CJET N/A
- RLMD N/A
- Industry
- CJET Auto Manufacturing
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CJET Consumer Discretionary
- RLMD Health Care
- Exchange
- CJET Nasdaq
- RLMD Nasdaq
- Market Cap
- CJET 12.2M
- RLMD 11.5M
- IPO Year
- CJET N/A
- RLMD N/A
- Fundamental
- Price
- CJET $1.82
- RLMD $0.30
- Analyst Decision
- CJET
- RLMD Hold
- Analyst Count
- CJET 0
- RLMD 4
- Target Price
- CJET N/A
- RLMD $4.25
- AVG Volume (30 Days)
- CJET 11.0K
- RLMD 2.1M
- Earning Date
- CJET 03-04-2025
- RLMD 03-18-2025
- Dividend Yield
- CJET N/A
- RLMD N/A
- EPS Growth
- CJET N/A
- RLMD N/A
- EPS
- CJET N/A
- RLMD N/A
- Revenue
- CJET $10,275,000.00
- RLMD N/A
- Revenue This Year
- CJET N/A
- RLMD N/A
- Revenue Next Year
- CJET N/A
- RLMD N/A
- P/E Ratio
- CJET N/A
- RLMD N/A
- Revenue Growth
- CJET 31.31
- RLMD N/A
- 52 Week Low
- CJET $1.50
- RLMD $0.28
- 52 Week High
- CJET $23.94
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- CJET 52.26
- RLMD 30.81
- Support Level
- CJET $1.78
- RLMD $0.28
- Resistance Level
- CJET $1.84
- RLMD $0.36
- Average True Range (ATR)
- CJET 0.10
- RLMD 0.04
- MACD
- CJET 0.03
- RLMD 0.02
- Stochastic Oscillator
- CJET 89.66
- RLMD 7.21
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.